Esteem Totally Implantable Hearing System
Launched by ENVOY MEDICAL CORPORATION · Mar 24, 2010
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
Title: Esteem® Totally Implantable Hearing System Clinical Trial
Purpose: To evaluate the safety and efficacy of the Esteem® Totally Implantable Hearing System (hereafter called the Esteem® System) in subjects suffering from mild to severe hearing loss.
Trial Design: This pivotal trial is designed as a prospective, multi-center, non-randomized, clinical trial to evaluate the safety and efficacy of the Esteem® System. For this trial the subject will act as his or her own control.
This trial has been designed to meet the United States' regulatory requirements.
Enrollment Size: It is curre...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject is 18 years old
- • Subject understands the nature of the procedure and has signed the Subject Informed Consent Form prior to the procedure
- • Subject is willing and able to comply with specified follow-up evaluations and understands the audiological test procedures and use of the Esteem System.
- * Subject has mild to severe sensorineural hearing loss between 500 and 4000 Hz in the ear to be implanted with pure tone air-conduction threshold levels within the limits of a Hearing Aid (HA) as follow:
- • Freq (Hz) 500 1000 2000 3000 4000 LL\* (dB HL) 30 35 35 35 35 UL\* (dB HL) 100 100 100 100 100
- • \*LL = Lower Level; UL = Upper Level
- • Subject's air-bone gap is no greater than 10 dB at 4 of the 5 following frequencies: 500, 1000, 2000, 3000 and 4000 Hz.
- • Subject has an unaided maximum word recognition score of greater than or equal to 60% with recorded delivery using a phonetically balanced word list at SRT + 40 dB or at maximum tolerable presentation level.
- • Subject is a current user of a properly functioning and appropriately fit hearing aid. This is defined as the subject has used this aid for at least four (4) hours (average) per day (in the ear to be implanted) for at least three (3) months for a new aid or one (1) month for an adjusted aid.
- • Subject's hearing aid, in the ear to be implanted, shall appropriately fit optimally.
- • Subject has normally functioning eustachian tube
- • Subject has normal tympanic membrane
- • Subject has a normal middle ear anatomy
- • Subject has adequate space for Esteem System implant determined via fine cut temporal bone CT scan
- • Subject is a native speaker of the English language.
- • Subject is a hearing aid user in the ear to be implanted.
- Exclusion Criteria:
- • Subject has a history of post-adolescent chronic middle ear infections, inner ear disorders or recurring vertigo requiring treatment, disorders such as mastoiditis, Hydrops or Meniere's syndrome or disease
- • Subject has a history of otitis externa or eczema for the outer ear canal and the investigator believes this will affect the Esteem System implantation
- • Subject has cholesteatoma or destructive middle ear disease
- • Subject has life expectancy of two (2) years due to other medical conditions
- • Subject has retrocochlear or central auditory disorders
- • Subject is known to be suffering from any psychological, developmental, physical, or emotional disorder that the investigator feels would interfere with the surgery or follow-up testing
- • Subject has a known history of fluctuating air conduction and/or bone conduction hearing loss over a one-year period of 15 dB in either direction at 2 or more frequencies (from 500 - 4000 Hz)
- • Subject has sudden hearing loss due to unknown cause
- • Subject has a history of disabling tinnitus, defined as tinnitus which required treatment.
- • Subject is unable to adequately perform audiological testing
- • Subject has a medical condition or undergoing a treatment that may affect healing and the investigator does not believe the subject is a good candidate for the trial.
- • Subject has diabetes that is not well controlled with medication or diet and the investigator does not believe in his best medical judgment that the subject would be a good candidate for the trial
- • Subject is pregnant at the time of device implant
- • Subject has a history of keloid formation
- • Subject has known hypersensitivity to silicone rubber, polyurethane, stainless steel, titanium and/or gold
About Envoy Medical Corporation
Envoy Medical Corporation is a pioneering healthcare organization dedicated to advancing innovative solutions in the field of neuromodulation and neuroprosthetics. With a strong emphasis on research and development, the company focuses on creating cutting-edge medical devices that enhance the quality of life for individuals with neurological conditions. Committed to clinical excellence and patient-centered care, Envoy Medical Corporation collaborates with leading experts and institutions to conduct rigorous clinical trials, ensuring the safety and efficacy of its products. Through its dedication to innovation and collaboration, the company aims to transform the landscape of neurological treatment and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newport Beach, California, United States
Burlington, Massachusetts, United States
Newport Beach, California, United States
Greensboro, North Carolina, United States
Greensboro, North Carolina, United States
Patients applied
Trial Officials
Jack A. Shohet, M.D.
Principal Investigator
Eric M. Kraus, M.D., M.S.
Principal Investigator
F.A.C.S.
Peter J. Catalano, M.D.
Principal Investigator
F.A.C.S.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials